JP2005047893A - 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 - Google Patents
化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 Download PDFInfo
- Publication number
- JP2005047893A JP2005047893A JP2004189843A JP2004189843A JP2005047893A JP 2005047893 A JP2005047893 A JP 2005047893A JP 2004189843 A JP2004189843 A JP 2004189843A JP 2004189843 A JP2004189843 A JP 2004189843A JP 2005047893 A JP2005047893 A JP 2005047893A
- Authority
- JP
- Japan
- Prior art keywords
- particles
- active compound
- agents
- particle
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 143
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 239000000843 powder Substances 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 210000004209 hair Anatomy 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 7
- 210000002374 sebum Anatomy 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 5
- 239000003410 keratolytic agent Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 208000001840 Dandruff Diseases 0.000 claims description 3
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 claims description 3
- 229920000299 Nylon 12 Polymers 0.000 claims description 3
- 239000003212 astringent agent Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 229920002292 Nylon 6 Polymers 0.000 claims description 2
- 229920002302 Nylon 6,6 Polymers 0.000 claims description 2
- 229920000572 Nylon 6/12 Polymers 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003213 antiperspirant Substances 0.000 claims description 2
- 230000003779 hair growth Effects 0.000 claims description 2
- 229940124563 hair growth stimulant Drugs 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 229910003471 inorganic composite material Inorganic materials 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims 1
- 230000001166 anti-perspirative effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 abstract description 3
- 230000000699 topical effect Effects 0.000 abstract description 3
- 210000004907 gland Anatomy 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 17
- 230000003325 follicular Effects 0.000 description 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- IXIGWKNBFPKCCD-UHFFFAOYSA-N 2-hydroxy-5-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 IXIGWKNBFPKCCD-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 8
- 239000004005 microsphere Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 229960003500 triclosan Drugs 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 7
- 238000005470 impregnation Methods 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 crimbazole Chemical compound 0.000 description 3
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 235000019160 vitamin B3 Nutrition 0.000 description 3
- 239000011708 vitamin B3 Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 238000004438 BET method Methods 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 229920001651 Cyanoacrylate Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 239000011146 organic particle Substances 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000003361 porogen Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940043810 zinc pyrithione Drugs 0.000 description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- AOIDYWIUVADOPM-UHFFFAOYSA-N 2-hydroxyethyl 2,3-dimethylbut-2-enoate Chemical compound CC(C)=C(C)C(=O)OCCO AOIDYWIUVADOPM-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical group C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 description 1
- UDYUIWXQUBNDHC-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UDYUIWXQUBNDHC-UHFFFAOYSA-N 0.000 description 1
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical class C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- CKZZREIPBTYJEQ-UHFFFAOYSA-N Totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(C)C=C2 CKZZREIPBTYJEQ-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- AZFUOHYXCLYSQJ-UHFFFAOYSA-N [V+5].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O Chemical compound [V+5].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O AZFUOHYXCLYSQJ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical class C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960002046 eflornithine hydrochloride Drugs 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- AFSIMBWBBOJPJG-UHFFFAOYSA-N ethenyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC=C AFSIMBWBBOJPJG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- VGAQVRLFBSWBRN-UHFFFAOYSA-N iodo(3-methylhex-4-yn-2-yl)carbamic acid Chemical compound CC#CC(C)C(C)N(C(=O)O)I VGAQVRLFBSWBRN-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229950006862 rilopirox Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940074347 totarol Drugs 0.000 description 1
- ZRVDANDJSTYELM-FXAWDEMLSA-N totarol Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)C1=C2C(C(C)C)=C(O)C=C1 ZRVDANDJSTYELM-FXAWDEMLSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- ZRVDANDJSTYELM-UHFFFAOYSA-N trans-totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(O)C=C2 ZRVDANDJSTYELM-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 150000003754 zirconium Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/14—Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【解決手段】個別化された多孔性粒子であって、10μm以下の体積平均直径、及び1m2/g以上の比表面積を有すること及び、該粒子の内部に存在するところの、少なくとも1の化粧料的に又は医薬的に活性な化合物を含むことを特徴とする粒子。及び特に毛嚢脂線単位に前記活性な化合物を輸送し放出するためのそれらの使用。
【選択図】 なし
Description
を有し得る。
− シリカ粒子例えばアサヒガラスにより“サンスフィアHシリーズ”の名前で販売されるもの、及び鈴木油脂により“ゴッドボール”の名前で販売されるもの、
− ハイドロキシアパタイト粒子、例えばMERCK社により販売されるもの(製品番号1051990010、平均粒子サイズ15μm)、さもなければLABORATORY SKIN CARE又はアサヒガラス及びセキスイによりそれぞれ“ヒドロキシゾーム”(LSC及びアサヒガラス)、AP20C及びAP12C(セキスイ)の名前で販売されるもの、及びセキスイプラスチック社による“ASP(商標)”
− アルミナ−シリカ粒子、例えば3Mにより“Zeeosphere(商標)”の名前で販売されるもの
− 酸化チタン粒子、例えば石原産業により販売されるもの
− これらの鉱物の混合物からなる粒子
から選択されることができる。
− 抗生剤、例えばトリクロサン、IPBC(ヨウ化−3−プロピニル−2−ブチルカーバメート)、ベンズアルコニウムクロライド、クロロヘキシジン、トタロール(商標)(トタラ−8,11,13−トリエン−13−オールを含む植物抽出物)等、
− 抗菌剤、例えばピロクトンオラミン、ジンクピリチオン、クリムバゾール、リロピロックス、ケトコナゾール、イトラコナゾール等、
− 皮脂調節剤、例えばイミノジベンジル又は米国特許第6355687号に記載されるフルオレン誘導体、米国特許第6355686号に記載される置換された2級アミン誘導体、欧州特許出願公開第1219296号に記載されるグルクロン酸及びグルコサミン誘導体及びその塩、又は国際特許出願公開第02/067889号に記載されるニアシンナミドと、サリチル酸のC11〜C30アルキル又はアルケニルエステルとの組み合わせ、
− 皮脂刺激剤、例えばDHEA及びその合成又は天然誘導体、ビタミンD1のα−ヒドロキシ化誘導体例えば米国特許第6369099号に記載されるもの、
− 角質溶解剤、例えばサリチル酸及びその誘導体、例えばより詳細には5−n−オクタノイルサリチル酸、アルファ−ヒドロキシ酸、例えばグリコール酸、乳酸又はリンゴ酸、及びレゾルシノール、
− ニキビ治療剤、例えばレチノール及びその誘導体、レチノン酸及びそのオールトランス又は13−シス異性体、過酸化ベンゾイル、米国特許第6399774号に記載されているチトクロームP450阻害剤及びそれらの誘導体及びアゼライン酸、
− マクロライド構造を有してもよいし、あるいは有しなくてもよいところの抗生物質、米国特許第6399652号に記載されているアベルメクチン化合物、国際特許出願公開第01/56556号に記載されているクロロエステリル及びワックスエステル合成の阻害剤としての、[(2,4,6−トリイソプロピルフェニル)−アセチル]スルファミン酸2,6−ジイソプロピルフェニルエステル又はその塩、
− 脱毛阻害剤及びまた育毛刺激剤例えばミノキシジル、ビオチン、フィナステリド、2,4ジピリミジンN−オキサイド、パンテノール及びそれらの誘導体、フラバノンT、又はより一般的にアンチ−5−アルファ−レダクターゼのタイプI又はIIの活性を有する任意の植物抽出物、
− 頭髪又は体毛の成長を阻害する剤、例えば米国特許第6407056号に記載されているセリンプロテアーゼ、カフェイン酸、ケルセチン、プロピルガレート、ノルジヒドログアイアレチック酸又はNDGA、インドメタシン、塩酸エフロルニチン、米国特許第6171595号に記載されている植物抽出物、例えばクローブ、ローズヒップ、ワレモコウ、ガンビール等、米国特許第6075052号に記載されている化合物、米国特許第6020006号に記載されているテトラミゾール、オルトバナジン酸ナトリウム、レバミゾール、クロモグリケート2ナトリウム、硝酸バナジウム、及び硝酸ガリウム、また米国特許第4885289号、第4720489号,第5132293号、第5096911号、第5095007号、第5143925号、第5328686号、第5440090号、第5364885号、第5411991号、第5648394号、第5468476号、第5475763号、第5455608号、第5674477号、第5728736号、及び第5652273号、
及び国際特許出願公開第94/27586号、第94/27563号及び第98/03149号に記載されている化合物。また以下のものも使用され得る。米国特許第6375948号に記載されているセイヨウネズの抽出物、
− 抗フケ剤例えばジンクピリチオン、
− 抗酸化剤、例えばブチルヒドロキシトルエン(BHT)、カロテノイド例えばβカロテン、リコペン、カンサキサンチン、ユビキノン、ジブチルペンタエリスリチルヒドロキシシンナメート、ビタミンE、トロロックス、ビタミンC及びその誘導体、
− アストリンゼント及び毛穴収縮剤、例えば国際特許出願公開第02/32392号に記載されているもの
− 制汗剤、例えばアルミニウム塩及びジルコニウム塩、
− 上に述べられた以外のビタミン、例えばビタミンB3、ビタミンK、ビタミンH,ビタミンPP、ビタミンD、ビタミンB6、及びそれらの誘導体、及び
− 抗炎症剤、例えばα−ビサボロール、グリチルリジン酸2カリウム、グリチルレチン酸およびその誘導体、エラグ酸、ウルソル酸、イブプロフェン、ナプロキセン、フェノプロフェン、カルプロフェン、ケトプロフェン、ステロイド系抗炎症剤、例えばコーチゾン、プレグネノロン、デソナイド、及びアルコルアミン及びチロシンの混合物、例えば欧州特許出願公開第1192939号に記載されているもの。
− 基本的に毛嚢脂腺単位の外で作用することを意図された少なくとも1の化粧量的に又は医薬的に活性な化合物、及び/又は
− 少なくとも1の化粧量的に又は医薬的に許容できる添加物及び/又は
− 生薬の担体、任意の適切のタイプでよい、
もまた含みうる。
20gのサリチル酸、1lのアセトン及び200gの多孔性シリカ(サンスフィアH33)の溶液が調整された。この溶液が攪拌下、活性剤が完全に溶解されるまで環境温度に保たれた。溶液は次に丸底フラスコに移され、アセトンは40℃においてロータリーエバポレーター中で蒸発除去された、溶媒の完全な蒸発後、多孔性シリカ粒子からなる粉末がこのようにして得られ、その孔は固体状態のサリチル酸を含む。得られた粒子の重量組成は、粒子の合計重量に対して10重量%のサリチル酸及び90重量%のシリカである。
粒子組成物
2.5gのトリクロサンが50mlのアセトン中に溶解される。7.5gの“Orgasol(商標)”がこの混合物に導入される。分散物は次にロータリーエバポレーターに導びかれ、アセトンを除去する。するとトリクロサンを与えられている粉末が得られる。
Claims (26)
- 個別化された多孔性粒子であって、10μm以下の体積平均直径、及び1m2/g以上の比表面積を有すること及び、該粒子の内部に少なくとも存在するところの、少なくとも1の化粧料的に又は医薬的に活性な化合物を含むことを特徴とする粒子。
- 2.5〜1000m2/gの範囲の比表面積を有することを特徴とする、請求項1に記載の粒子。
- 3〜750m2/gの範囲の比表面積を有することを特徴とする、請求項1又は2のいずれか1項に記載の粒子。
- 0.15g/cm3以上の体積当たりの質量を有することを特徴とする請求項1〜3のいずれか1項に記載の粒子。
- 0.2〜5g/cm3の範囲の体積当たりの質量を有することを特徴とする請求項1〜4のいずれか1項に記載の粒子。
- 0.1μm以上の体積平均直径を有することを特徴とする、請求項1〜5のいずれか1項に記載の粒子。
- 0.5〜8μmの範囲の体積平均直径を有することを特徴とする、請求項1〜6のいずれか1項に記載の粒子。
- 0.1〜50μmの範囲の数平均サイズを有することを特徴とする、請求項1〜7のいずれか1項に記載の粒子。
- 0.1〜20μmの範囲の数平均サイズを有することを特徴とする、請求項1〜8のいずれか1項に記載の粒子。
- 0.5〜10μmの範囲の数平均サイズを有することを特徴とする、請求項1〜9のいずれか1項に記載の粒子。
- 1〜4の範囲の分散度を有することを特徴とする、請求項1〜10のいずれか1項に記載の粒子。
- 3以下の分散度を有することを特徴とする、請求項1〜11のいずれか1項に記載の粒子。
- 粉末の形で提供されることを特徴とする、請求項1〜12のいずれか1項に記載の粒子。
- 有機多孔性粒子から由来することを特徴とする、請求項1〜13のいずれか1項に記載の粒子。
- 前記有機多孔性粒子が、ナイロン6、ナイロン6−6、ナイロン12、及びナイロン6−12の粒子、及びポリ(メチルメタクリレート)の粒子から選択されることを特徴とする、請求項14に記載の粒子。
- 無機多孔性粒子から由来することを特徴とする、請求項1〜13のいずれか1項に記載の粒子。
- 前記無機多孔性粒子が、シリカ、アルミナ−シリカ、ハイドロキシアパタイト、二酸化チタンの粒子又はそれらの混合物から選択されることを特徴とする、請求項16に記載の粒子。
- 有機及び無機の複合材料からできた多孔性粒子から由来することを特徴とする、請求項1〜17のいずれか1項に記載の粒子。
- 活性化合物:活性化合物を与えられていない多孔性粒子の重量比が、1/1000〜10/1であることを特徴とする、請求項1〜18のいずれか1項に記載の粒子。
- 活性化合物:活性化合物を与えられていない多孔性粒子の重量比が、1/100〜1/1であることを特徴とする、請求項1〜19のいずれか1項に記載の粒子。
- 抗微生物剤、抗菌剤、皮脂調節剤、皮脂刺激剤、抗皮膚老化剤、特に角質溶解剤又は落屑剤、ニキビ治療剤、抗生物質、毛損失阻害剤/毛成長刺激剤、毛髪又は体毛の成長を阻害する剤、抗フケ剤、抗酸化剤、アストリンゼント、毛穴収斂剤、制汗剤、ビタミン、抗炎症剤、及びそれらの混合物から選択される少なくとも1の化粧料的に又は医薬的に活性な化合物を含むことを特徴とする、請求項1〜20のいずれか1項に記載の粒子。
- 請求項1〜20のいずれか1項において定義された粒子を含むことを特徴とする、化粧料組成物又は医薬組成物。
- 前記組成物の合計重量に対する前記粒子の重量割合が0.1〜50%であることを特徴とする、請求項22に記載の化粧料組成物又は医薬組成物。
- 前記組成物の合計重量に対する前記粒子の重量割合が0.2〜20%であることを特徴とする、請求項22に記載の化粧料組成物又は医薬組成物。
- ローション、O/Wエマルジョン、W/Oエマルジョン、又は水性又は水性アルコールジェルの形、又は無水の形、例えばスティック、スプレー又はコンパクト又はフリーパウダーの形で供給されることを特徴とする、請求項22〜24のいずれか1項に記載の化粧料組成物又は医薬組成物。
- メイクアップ落とし製品、特にオイル、ジェル、又はメイクアップ落とし又はフォーミングローション、又はそれ以外のメイクアップ製品例えばファンデーション、着色されたクリーム、マスカラ、又はアイライナーの形で供給されることを特徴とする、請求項22〜24のいずれか1項に記載の化粧料組成物又は医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0307747A FR2856594B1 (fr) | 2003-06-26 | 2003-06-26 | Particules poreuses chargees en compose(s) actif(s) cosmetique(s) ou pharmaceutique(s) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007034350A Division JP5032859B2 (ja) | 2003-06-26 | 2007-02-15 | 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005047893A true JP2005047893A (ja) | 2005-02-24 |
JP4060828B2 JP4060828B2 (ja) | 2008-03-12 |
Family
ID=33427630
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004189843A Expired - Lifetime JP4060828B2 (ja) | 2003-06-26 | 2004-06-28 | 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 |
JP2007034350A Expired - Lifetime JP5032859B2 (ja) | 2003-06-26 | 2007-02-15 | 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 |
JP2010121953A Expired - Lifetime JP5273683B2 (ja) | 2003-06-26 | 2010-05-27 | 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007034350A Expired - Lifetime JP5032859B2 (ja) | 2003-06-26 | 2007-02-15 | 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 |
JP2010121953A Expired - Lifetime JP5273683B2 (ja) | 2003-06-26 | 2010-05-27 | 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1493433A1 (ja) |
JP (3) | JP4060828B2 (ja) |
FR (1) | FR2856594B1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507012A (ja) * | 2005-09-06 | 2009-02-19 | セデルマ | 毛包脂腺ユニットの活性を調節する活性物質としてのプロトベルベリン(protoberberine)の使用 |
WO2009113522A1 (ja) * | 2008-03-11 | 2009-09-17 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
JP2010116373A (ja) * | 2008-11-14 | 2010-05-27 | Kose Corp | 多層被覆粒子及びその製造方法並びにそれを含有する皮膚外用剤 |
WO2010092925A1 (ja) * | 2009-02-12 | 2010-08-19 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
JP2012504158A (ja) * | 2008-09-30 | 2012-02-16 | イントリンシツク・マテリアルズ・グローバル・リミテツド | 多孔質材料 |
JP2012524765A (ja) * | 2009-04-21 | 2012-10-18 | アルケマ フランス | 少なくとも一種の化粧品または医薬品を含浸したポリアミドのフリー粉末粒子の製造方法と、水以外の少なくとも一種の化粧品または医薬品の含有量が少なくとも25重量%であるポリアミドのフリー粉末粒子 |
JP2013505293A (ja) * | 2008-09-23 | 2013-02-14 | ラボラトリー スキン ケア インコーポレイテッド | 活性剤を充填した、均一、硬質、球形のナノ多孔質リン酸カルシウム粒子、およびその製造方法と使用方法 |
JP2013510862A (ja) * | 2009-11-10 | 2013-03-28 | ラボラトリー スキン ケア インコーポレイテッド | 均一、硬質、球状のナノ多孔性リン酸カルシウム粒子を含む日焼け止め組成物、ならびにその製造方法および使用方法 |
JPWO2011111828A1 (ja) * | 2010-03-11 | 2013-06-27 | ライオン株式会社 | 化粧料組成物 |
JP2015110603A (ja) * | 2015-01-08 | 2015-06-18 | ラボラトリー スキン ケア インコーポレイテッド | 活性剤を充填した、均一、硬質、球状のナノ多孔質リン酸カルシウム粒子の製造方法 |
JP2019137677A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社 資生堂 | 香料除去用組成物、消香体および化粧品 |
WO2019159860A1 (ja) * | 2018-02-14 | 2019-08-22 | 株式会社 資生堂 | 香料除去用組成物、消香体および化粧品 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2874321B1 (fr) | 2004-08-17 | 2010-11-26 | Oreal | Composition topique comprenant des particules poreuses chargees et un compose absorbant le sebum |
FR2875134B1 (fr) * | 2004-09-16 | 2007-08-24 | Oreal | Utilisation cosmetique d'une composition renfermant un derive ascorbique et des particules de polyamide |
FR2876284B1 (fr) * | 2004-10-08 | 2007-01-19 | Oreal | Poudre compacte contenant des particules de polyamide renfermant un actif |
WO2006037665A1 (en) * | 2004-10-08 | 2006-04-13 | L'oreal | Compact powder comprising polyamide particles containing an active agent |
JP2009501209A (ja) * | 2005-07-12 | 2009-01-15 | ロレアル | シワの処理のための美容方法 |
FR2892019B1 (fr) * | 2005-10-14 | 2007-11-30 | Oreal | Procede de traitement des rides et kit de mise en oeuvre |
FR2924941B1 (fr) * | 2007-12-18 | 2010-01-22 | Oreal | Procede cosmetique de soin d'une peau ridee |
FR2930146B1 (fr) * | 2008-04-21 | 2012-05-11 | Ab7 Ind | Support fibreux comprenant un, ou plusieurs, actif(s) cosmetique(s) microenspherule(s). |
IT1406067B1 (it) * | 2010-07-14 | 2014-02-06 | Torino Politecnico | Composizioni eudermiche. |
FR2966722B1 (fr) * | 2010-10-27 | 2012-11-16 | Oreal | Composition cosmetique comprenant un alun et des particules poreuses chargees de compose d?acide salicylique |
JP2013001685A (ja) * | 2011-06-17 | 2013-01-07 | Epia:Kk | 鉄粉入り化粧品クリームと、そのスティック |
AU2012296404A1 (en) * | 2011-08-16 | 2014-07-24 | Laboratory Skin Care, Inc. | Fine dry particulate adenosine compositions and topical formulations including the same |
JP6222981B2 (ja) * | 2013-05-10 | 2017-11-01 | 丸善製薬株式会社 | 粉末化粧料用粉体および粉末化粧料 |
FR3019040B1 (fr) * | 2014-03-31 | 2016-03-11 | Arkema France | Composition cosmetique pour l'eclaircissement de la peau |
JP5940236B2 (ja) * | 2014-06-30 | 2016-06-29 | 日揮触媒化成株式会社 | 多孔質シリカ系粒子、その製造方法及びそれを配合した化粧料 |
AU2015344139B2 (en) | 2014-11-05 | 2017-07-20 | Jgc Catalysts And Chemicals Ltd. | Porous Silica Particle and Cleansing Cosmetic |
KR101648676B1 (ko) * | 2015-03-13 | 2016-08-16 | (주)아모레퍼시픽 | 다공성 고분자에 무기분체가 함침된 복합분체, 이를 함유하는 화장료 조성물 및 이의 제조방법 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690825A (en) * | 1985-10-04 | 1987-09-01 | Advanced Polymer Systems, Inc. | Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen |
JPS62249914A (ja) * | 1986-04-22 | 1987-10-30 | Sekisui Plastics Co Ltd | 粉末固形状化粧料 |
FR2600532B1 (fr) * | 1986-06-26 | 1988-08-26 | Oreal | Utilisation, dans la preparation de poudres pour le maquillage ou les soins du corps ou du visage, d'un materiau synthetique thermoplastique sous la forme de microspheres creuses, et compositions sous forme de poudre non compactee contenant un tel materiau. |
FR2619385B1 (fr) * | 1987-08-11 | 1992-01-17 | Atochem | Poudre de polyamide constituee de particules a structure " rose des sables ". procede d'obtention de la poudre de polyamide |
ZA886284B (en) * | 1987-08-31 | 1990-04-25 | Advanced Polymer Systems Inc | Controlled release formulations |
LU87429A1 (fr) * | 1989-01-17 | 1990-07-24 | Oreal | Produit a base de particules de polymere comportant des pigments melaniques,son procede de preparation et son utilisation,en particulier en cosmetique |
EP0460923B1 (en) * | 1990-06-04 | 1994-12-28 | Tokuyama Corporation | Basic magnesium carbonate and process for preparation thereof |
FR2722102B1 (fr) * | 1994-07-11 | 1996-08-23 | Cird Galderma | Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
FR2762504B1 (fr) * | 1997-04-29 | 1999-09-10 | Cird Galderma | Procede d'epilation |
WO1998058628A1 (en) * | 1997-06-20 | 1998-12-30 | Mary Kay Inc. | Cosmetic composition containing a whitening agent and an exfoliant |
WO2000071093A1 (en) * | 1999-05-25 | 2000-11-30 | The Procter & Gamble Company | Niacinamide compositions with reduced tack |
WO2001052795A2 (en) * | 2000-01-19 | 2001-07-26 | The Procter & Gamble Company | Skin care compositions |
FR2822376B1 (fr) * | 2001-03-23 | 2004-06-11 | Oreal | Utilisation de particules de polyamide comme agent anti-irritant dans une composition cosmetique ou dermatologique |
KR100845731B1 (ko) * | 2001-12-14 | 2008-07-11 | 주식회사 코리아나화장품 | 미백 활성물질을 함유하는 분말형 화장료 조성물 |
KR100829719B1 (ko) * | 2001-12-20 | 2008-05-15 | 주식회사 코리아나화장품 | 주름개선 활성물질을 함유하는 분말형 화장료 조성물 |
FR2927626B1 (fr) * | 2008-02-15 | 2011-02-25 | Arkema France | Poudre fine de polyamide issu de matieres renouvelables et procede de fabrication d'une telle poudre. |
-
2003
- 2003-06-26 FR FR0307747A patent/FR2856594B1/fr not_active Expired - Lifetime
-
2004
- 2004-06-23 EP EP04300394A patent/EP1493433A1/fr not_active Withdrawn
- 2004-06-28 JP JP2004189843A patent/JP4060828B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-15 JP JP2007034350A patent/JP5032859B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-27 JP JP2010121953A patent/JP5273683B2/ja not_active Expired - Lifetime
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507012A (ja) * | 2005-09-06 | 2009-02-19 | セデルマ | 毛包脂腺ユニットの活性を調節する活性物質としてのプロトベルベリン(protoberberine)の使用 |
WO2009113522A1 (ja) * | 2008-03-11 | 2009-09-17 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
US8722094B2 (en) | 2008-03-11 | 2014-05-13 | Aska Pharmaceutical Co., Ltd. | Solid dispersion and pharmaceutical composition of the same, and production processes thereof |
US10758478B2 (en) | 2008-09-23 | 2020-09-01 | Laboratory Skin Care, Inc. | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same |
JP2013505293A (ja) * | 2008-09-23 | 2013-02-14 | ラボラトリー スキン ケア インコーポレイテッド | 活性剤を充填した、均一、硬質、球形のナノ多孔質リン酸カルシウム粒子、およびその製造方法と使用方法 |
US10028903B2 (en) | 2008-09-23 | 2018-07-24 | Laboratory Skin Care, Inc. | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same |
US9243144B2 (en) | 2008-09-30 | 2016-01-26 | Psimedica Limited | Composition containing loaded and capped porous silica particles |
JP2012504158A (ja) * | 2008-09-30 | 2012-02-16 | イントリンシツク・マテリアルズ・グローバル・リミテツド | 多孔質材料 |
JP2010116373A (ja) * | 2008-11-14 | 2010-05-27 | Kose Corp | 多層被覆粒子及びその製造方法並びにそれを含有する皮膚外用剤 |
WO2010092925A1 (ja) * | 2009-02-12 | 2010-08-19 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
KR101817362B1 (ko) * | 2009-04-21 | 2018-02-21 | 아르끄마 프랑스 | 하나 이상의 미용 또는 약학 제제에 의해 함침된 폴리아미드의 자유 분말 입자의 제조 방법, 및 25 중량% 이상의 하나 이상의 미용 또는 약학 제제의 함량을 갖는 폴리아미드의 자유 분말 입자 |
JP2012524765A (ja) * | 2009-04-21 | 2012-10-18 | アルケマ フランス | 少なくとも一種の化粧品または医薬品を含浸したポリアミドのフリー粉末粒子の製造方法と、水以外の少なくとも一種の化粧品または医薬品の含有量が少なくとも25重量%であるポリアミドのフリー粉末粒子 |
US9095510B2 (en) | 2009-11-10 | 2015-08-04 | Laboratory Skin Care, Inc. | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same |
US9642784B2 (en) | 2009-11-10 | 2017-05-09 | Laboratory Skin Care, Inc. | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same |
JP2013510862A (ja) * | 2009-11-10 | 2013-03-28 | ラボラトリー スキン ケア インコーポレイテッド | 均一、硬質、球状のナノ多孔性リン酸カルシウム粒子を含む日焼け止め組成物、ならびにその製造方法および使用方法 |
US10123950B2 (en) | 2009-11-10 | 2018-11-13 | Laboratory Skin Care, Inc. | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same |
US10857077B2 (en) | 2009-11-10 | 2020-12-08 | Laboratory Skin Care, Inc. | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same |
JP5721696B2 (ja) * | 2010-03-11 | 2015-05-20 | ライオン株式会社 | 化粧料組成物 |
JPWO2011111828A1 (ja) * | 2010-03-11 | 2013-06-27 | ライオン株式会社 | 化粧料組成物 |
JP2015110603A (ja) * | 2015-01-08 | 2015-06-18 | ラボラトリー スキン ケア インコーポレイテッド | 活性剤を充填した、均一、硬質、球状のナノ多孔質リン酸カルシウム粒子の製造方法 |
JP2019137677A (ja) * | 2018-02-14 | 2019-08-22 | 株式会社 資生堂 | 香料除去用組成物、消香体および化粧品 |
WO2019159860A1 (ja) * | 2018-02-14 | 2019-08-22 | 株式会社 資生堂 | 香料除去用組成物、消香体および化粧品 |
JP7198105B2 (ja) | 2018-02-14 | 2022-12-28 | 株式会社 資生堂 | 化粧品 |
Also Published As
Publication number | Publication date |
---|---|
EP1493433A1 (fr) | 2005-01-05 |
FR2856594A1 (fr) | 2004-12-31 |
JP4060828B2 (ja) | 2008-03-12 |
JP5273683B2 (ja) | 2013-08-28 |
JP5032859B2 (ja) | 2012-09-26 |
FR2856594B1 (fr) | 2006-03-03 |
JP2010254698A (ja) | 2010-11-11 |
JP2007161728A (ja) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5032859B2 (ja) | 化粧料的に又は医薬的に活性な化合物を与えられている多孔性粒子 | |
US8507006B2 (en) | Porous particles loaded with cosmetically or pharmaceutically active compounds | |
Hameed et al. | Scope of nanotechnology in cosmetics: dermatology and skin care products | |
US9056053B2 (en) | Nanoparticle compositions providing enhanced color for cosmetic formulations | |
JP2002293718A (ja) | 化粧品または皮膚科用組成物中における抗刺激剤としての繊維の使用 | |
EP1072259A2 (en) | Microcapsule and method of making the same | |
JPH09175931A (ja) | シリコーン界面活性剤をベースとしたラメラ相で被覆された微小粒子とそれらを含有する組成物 | |
WO2008079758A1 (en) | Nanocomposite pigments in a topical cosmetic application | |
FR2720937A1 (fr) | Composition cosmétique ou dermatologique sous forme de dispersion, aqueuse et stable, de particules de gel cubique à base de phytantriol et contenant un agent tensioactif à chaîne grasse en tant qu'agent dispersant et stabilisant. | |
JPH05148129A (ja) | 皮膚への局所適用による表皮上層の化粧的および(または)薬学的処置のための組成物およびその製造方法 | |
JP2002507202A (ja) | 美白剤及び落屑剤を含む化粧用組成物 | |
WO2008079760A2 (en) | Nanocomposite pigments in a topical cosmetic application | |
WO1996021422A1 (en) | Anhydrous cosmetic compositions with dermatologically active agents | |
JP2007145873A (ja) | 皮膚及び/又は半粘膜の外観を変えるための、ビニルピロリドン及びアルケンのコポリマーの化粧的使用 | |
JP2009501209A (ja) | シワの処理のための美容方法 | |
JP2000327550A (ja) | 皮膚外用剤 | |
JP2002322019A (ja) | 化粧品組成物または皮膚科学組成物における抗刺激剤としてのポリアミド粒子の使用 | |
Virmani et al. | Consumer nanoproducts for cosmetics | |
JP3834563B2 (ja) | アルブチンを利用した安定なナノ乳化粒子の製造方法及びナノ乳化粒子を含有する化粧料組成物 | |
WO2022067008A1 (en) | Compositions and methods for the treatment of hair loss and other conditions | |
WO2024034159A1 (ja) | 化粧料及び美容方法 | |
TWI719644B (zh) | 一種精油載體顆粒的製備方法、精油載體顆粒及其應用 | |
Ali et al. | Emulsification technology for cosmetics preparation | |
JP2002114625A (ja) | グリコグリセリドに基づく組成物とその使用、特に化粧的使用 | |
JP2023053927A (ja) | PPARα活性化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040825 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050914 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050922 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060322 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070410 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070514 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071220 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4060828 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111228 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111228 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121228 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121228 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131228 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |